CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for StemCyte International Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

StemCyte International Ltd
Ugland House
PO Box 309
GRAND CAYMAN, KY1-1104  Cayman Islands Ticker: 41784178
Business Summary
StemCyte International Ltd is a Cayman Island-based holding company. It is engaged in regenerative cell therapy and focuses on developing cell therapy products as well as providing both public and private cell banking services in the United States of America and Taiwan. It focuses on umbilical cord blood banking, is continuously developing cell therapy indications with the goal of sustainable business operations. It provides allogeneic cell materials to create solutions for cellular therapy. The Company is expanding the application of cell therapy in the development of new drugs. Its ongoing human trials include Phase II clinical trials for COVID-19, Phase II clinical trials for spinal cord injury, and Phase I clinical trials for acute stroke. Its umbilical cord blood cell therapy, RegeneCyte, has assisted in over 2,500 transplant treatments worldwide. Its subsidiaries include StemCyte, Inc. and Taiwan Immortal Cell Co., Ltd.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202412/31/2023-----

Industries
SIC Code Description
2836 Biological products, except diagnostic substances

General Information
Outstanding Shares: 190,525,486 (As of 12/5/2024)
Stock Exchange: TPO


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Sunday, December 22, 2024